Activation of a GPCR, ORL1 Receptor: A Novel Therapy to Prevent Heart Failure Progression
2024

New Therapy to Prevent Heart Failure Progression

Sample size: 12 publication Evidence: moderate

Author Information

Author(s): Saliha S. Pathan, Aarthi Pugazenthi, Beverly R. E. A. Dixon, Theodore G. Wensel, Todd K. Rosengart, Megumi Mathison

Primary Institution: Baylor College of Medicine

Hypothesis

The activation of the ORL1 receptor would suppress heart failure in a rat ischemic heart model.

Conclusion

The ORL1 activator, MCOPPB, significantly improved cardiac function after myocardial infarction in rats.

Supporting Evidence

  • MCOPPB significantly improved ejection fraction compared to saline.
  • MCOPPB decreased fibrosis and induced angiogenesis.
  • Body weight gain was less in the male MCOPPB group compared to the saline group.

Takeaway

Researchers found that a new drug called MCOPPB can help hearts recover better after damage, which might stop heart failure from getting worse.

Methodology

Adult Sprague Dawley rats underwent coronary artery ligation and were treated with either saline or MCOPPB for 3 months, with echocardiography performed at multiple time points.

Limitations

The study used a small number of animals and preliminary in vitro experiments were incomplete.

Participant Demographics

Adult Sprague Dawley rats, 8 weeks old, with 6 males and 6 females.

Statistical Information

P-Value

p < 0.001

Statistical Significance

p < 0.001

Digital Object Identifier (DOI)

10.3390/jcdd11110355

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication